BMY Related Analyst Ratings
-
Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Raises PT
-
Goldman Sachs Said Bristol-Myers (BMY) Is Most Likely Large Pharma To Be Acquired
-
Cowen & Co Downgrades Bristol-Myers (BMY) to Neutral
-
Wells Fargo Starts Bristol-Myers (BMY) with an Outperform
-
Leerink Swann Analyst Says Bristol-Myers Squibb (BMY) Shares Fully Valued vs. Peers
-
Morgan Stanley Downgrades Bristol-Myers (BMY) to Equalweight
-
Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)
-
Morgan Stanley Starts Bristol-Myers Squibb (BMY) at Overweight
-
Bank of America Resumes Coverage on Bristol-Myers (BMY) with a Neutral
-
Goldman Sachs Downgrades Bristol-Myers Squibb (BMY) to Neutral
-
Bernstein Downgrades Bristol-Myers Squibb (BMY) to Market Perform
-
Goldman Sachs added Bristol-Myers Squibb Co. (BMY) to its Conviction Buy List
-
Merrill Lynch Downgrades Bristol-Myers Squibb (BMY) to Neutral
-
Citi Upgrades Bristol-Myers Squibb (BMY) to Buy
-
Goldman Sachs Starts Coverage On Drug Makers; WYE & BMY at Buy, PFE at Sell, LLY & MRK at Neutral
-
Citi Issues List of 50 Highest Dividend Yield Stocks (MIC, FLY, AYR, GCI, OMX, STI, More...)
-
Matrix Lighthouse Rating Changes 10/16
-
Merrill Lynch Upgrades Bristol-Myers Squibb (BMY) to Buy
-
Analyst Expects Immediate $70/Share Offer for ImClone (IMCL) from Bristol-Myers Following News
-
Goldman Sachs Downgrades ImClone (IMCL) to Neutral
-
Matrix USA Rating Changes 8/1:
-
Citi Initiates Coverage on Bristol-Myers Squibb (BMY) with a Neutral
-
Matrix USA Rating Changes 7/9
-
Bernstein Upgrades Bristol-Myers (BMY) to Outperform
-
J.P. Morgan Initiates Coverage on Major Drug Manufacturers - BMY, LLY & WYE
-
Matrix USA Rating Changes 5/12
-
Matrix USA Rating Changes 3/4
-
Canaccord Adams Says Cell Genesys (CEGE) Will Have Partner By Mid-'08
-
Cowen Upgrades Bristol-Myers Squibb (BMY) to Outperform
-
S&P Equity Research Downgrades Bristol-Myers Squibb (BMY) to Hold
-
Goldman Sachs downgrades Bristol Myers Squibb Co. (BMY) to Sell
-
Argus Upgrades Bristol-Myers Squibb (BMY) to Buy
-
S&P Equity Research Downgrades Bristol-Myers Squibb (BMY) to Buy
-
Cowen Upgrades Bristol-Myers (BMY) to Neutral
-
Bristol-Myers (BMY) option volume Heavy on Elevated volatility of 30
-
BWS Financial Says ImClone (IMCL) Settlement Removes Barrier To Being Acquired
-
Goldman Sachs downgrades Bristol-Myers (BMY) to Sell
-
S&P Equity Research Downgrades Medarex (MEDX) to Hold
-
Bear Stearns upgrades Bristol-Myers (BMY) to Outperform
-
Citigroup Analyst Comments on Bristol-Myers Squib (BMY)l; Takeout Prospects Increased
-
Citigroup Upgrades Bristol-Myers Squibb Co (BMY) to Buy
-
S&P Equity Research Positive on Big Pharma Stocks With Expanding Oncology Franchises
-
Deutsche Bank upgrades Bristol-Myers Squibb (BMY) to Buy
-
BMO Capital Initiates Coverage on Bristol-Myers (BMY) with a Market Perform
-
UBS upgrades Bristol Myers (BMY) to Buy
-
Jim Cramer Makes Comments on PFE, BMY, CAB, ATK & ADM
-
Jim Cramer Makes Positive Comments on: DEO, MNST, YHOO, GM, OS & BMY
-
Jim Cramer makes comments on: AVP, MMC, BOL, HD & BMY
-
Jim Cramer Makes Positive Comments on 'Big Pharma' Stocks: ABT, JNJ, SGP, WYE, LLY & BMY
-
Prudential Securities Upgrades Bristol-Myers Squibb (BMY) to Overweight
Back to BMY Stock Lookup
